UB Paderborn / Katalog / Suche / in CDI

Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7065-7065

2023

Link zum Volltext

Verfügbarkeit prüfen

Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7066-7066

2023

Link zum Volltext

Verfügbarkeit prüfen

Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18728-e18728

2021

Link zum Volltext

Verfügbarkeit prüfen

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4519-4519

2021

Link zum Volltext

Verfügbarkeit prüfen

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS6591-TPS6591

2020

Link zum Volltext

Verfügbarkeit prüfen

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3113-TPS3113

2017

Link zum Volltext

Verfügbarkeit prüfen

Concordance study of HER2 fluorescence in situ hybridization (FISH) assays in upper gastrointestinal (UGI) adenocarcinomas

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4072-4072

2014

Link zum Volltext

Verfügbarkeit prüfen

Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.617-617

2014

Link zum Volltext

Verfügbarkeit prüfen

Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.630-630

2014

Link zum Volltext

Verfügbarkeit prüfen

Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS664-TPS664

2013

Link zum Volltext

Verfügbarkeit prüfen

HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS658-TPS658

2012

Link zum Volltext

Verfügbarkeit prüfen

The working and impact of the house of commons political and constitutional reform committee in the 2010-15 parliament

Ellis, Eloise Elizabeth Catherine

2018

Link zum Volltext
ProQuest

Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study

The Lancet (British edition), 2019-02, Vol.393 (10173), p.747-757

2019

Link zum Volltext

Verfügbarkeit prüfen

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

The Lancet (British edition), 2022-12, Vol.400 (10369), p.2199-2209

2022

Link zum Volltext

Verfügbarkeit prüfen

Trafficking and processing of bacterial proteins by mammalian cells: Insights from chondroitinase ABC

PloS one, 2017-11, Vol.12 (11), p.e0186759-e0186759

2017

Link zum Volltext

Verfügbarkeit prüfen

Empowering Better End‐of‐Life Dementia Care (EMBED‐Care): A mixed methods protocol to achieve integrated person‐centred care across settings

International journal of geriatric psychiatry, 2020-08, Vol.35 (8), p.820-832

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study

Arthritis research & therapy, 2014-07, Vol.16 (4), p.R138-R138

2014

Link zum Volltext

Verfügbarkeit prüfen

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

JNCI : Journal of the National Cancer Institute, 2013-06, Vol.105 (11), p.812-822

2013

Link zum Volltext

Verfügbarkeit prüfen

Physical Activity as a Predictor of Changes in Systolic Blood Pressure for African-American Adolescents Seeking Treatment for Obesity

Journal of adolescent health, 2019-09, Vol.65 (3), p.430-432

2019

Link zum Volltext

Verfügbarkeit prüfen

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet (British edition), 2021-02, Vol.397 (10274), p.605-612

2021

Link zum Volltext

Verfügbarkeit prüfen

African-American Adolescents’ Weight Loss Skills Utilization: Effects on Weight Change in a Sequential Multiple Assignment Randomized Trial

Journal of adolescent health, 2019-03, Vol.64 (3), p.355-361

2019

Link zum Volltext

Verfügbarkeit prüfen

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

The Lancet (British edition), 2019-04, Vol.393 (10179), p.1440-1452

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluating clinician experience in value-based health care: the development and validation of the Clinician Experience Measure (CEM)

BMC health services research, 2022-12, Vol.22 (1), p.1484-1484, Article 1484

2022

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Indirect treatment comparison (ITC) of momelotinib (MMB) vs fedratinib (FED) safety in patients (pts) with myelofibrosis (MF)

Impact of transfusion burden on health-related quality of life (HRQOL) and functioning in patients (pts) with myelofibrosis (MF): Post hoc analysis of SIMPLIFY-1 (S1) and -2 (S2)

Evolution of standard of care therapies used for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A real-world analysis of patient health records from 2016 to 2019

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs)

Updated analysis of the inducible T-cell co-stimulatory receptor (ICOS) agonist, GSK3359609 (GSK609), combination with pembrolizumab (PE) in patients (pts) with anti-PD-1/L1 treatment-naïve head and neck squamous cell carcinoma (HNSCC)

INDUCE-1: Report on safety run-in cohorts combining Inducible T-cell co-stimulatory receptor (ICOS) agonist GSK3359609 (GSK609) with platinum+5-FU chemotherapy (5-FU/plat), with or without pembrolizumab (PE), for the treatment of advanced solid tumors

INDUCE-3: A randomized, double-blind study of GSK3359609 (GSK609), an inducible T-cell co-stimulatory (ICOS) agonist antibody, plus pembrolizumab (PE) versus placebo (PL) plus PE for first-line treatment of PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

INDUCE-1: A phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with advanced solid tumors

Concordance study of HER2 fluorescence in situ hybridization (FISH) assays in upper gastrointestinal (UGI) adenocarcinomas

Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31

Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis

Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (HALT: LPT112515)

HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515)

The working and impact of the house of commons political and constitutional reform committee in the 2010-15 parliament

Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study

Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial

Trafficking and processing of bacterial proteins by mammalian cells: Insights from chondroitinase ABC

Empowering Better End‐of‐Life Dementia Care (EMBED‐Care): A mixed methods protocol to achieve integrated person‐centred care across settings

Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study

Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE

Physical Activity as a Predictor of Changes in Systolic Blood Pressure for African-American Adolescents Seeking Treatment for Obesity

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

African-American Adolescents’ Weight Loss Skills Utilization: Effects on Weight Change in a Sequential Multiple Assignment Randomized Trial

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Evaluating clinician experience in value-based health care: the development and validation of the Clinician Experience Measure (CEM)

Suchergebnisse filtern